Jaguar Health für Investierte und Interessierte Forum: Community User: Bsjunge

Bei investing zeigt die AH +22%

Nein, scroll weiter runter, wir sind bei 0,11$

Laut Nasdaq Afterhour sind wir doch bei +9,76%... https://www.nasdaq.com/market-activity/stocks/jagx/after-hours

@HoMie02 naja war gestern 30% plus dann ging das runter auf 1-5 % und trotzdem ist after hour 22% also wenn das so bleibt wäre jackpot

Ist doch in den USA heute Nacht schon alles abverkauft worden, wenn wir heute den gestrigen Wert erreichen und dann halten können wäre das schon ein riesen Erfolg.

Ihr seid aber wirklich sehr optimistisch. So einfach läuft das nicht. Heute nachmittags wird erst interessant

Mindestens 🚀

Heute schon 0,12?

Ich Tippe auch auf bis zu 0,20€ und dann eventuell leichte Korrektur.

Erstmal abwarten, das kann genauso schnell wieder abstürzen

Die Rakete hat Fahrt aufgenommen und die Frage ist, wie reicht der Treibstoff bis zu der nächsten News 🚀🚀🚀... ich denke die Woche könnten wir die 0.20€ erreichen

https://jaguarhealth.gcs-web.com/news-releases/news-release-details/jaguar-health-reports-approval-all-proposals-april-2024-special

Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders April 9, 2024 PDF Version Company not implementing a reverse split at this time Top line results forthcoming for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea SAN FRANCISCO, CA / ACCESSWIRE / April 9, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's Special Meeting of Stockholders held on April 9, 2024 (the "Special Meeting"). Four proposals were submitted to and approved by the stockholders of the Company at the Special Meeting. The proposals are described in detail in the Company's definitive proxy statement on Schedule 14A relating to the Special Meeting and supplemental information filed with the Securities and Exchange Commission on March 15, 2024. Stockholders may obtain a free copy of the proxy statement and other documents filed by Jaguar with the SEC at http://www.sec.gov. The proxy statement is also available on the Company's corporate website. "As we announced last week, the Company received formal notice that the Listing Qualifications Staff of The Nasdaq Stock Market LLC has granted Jaguar an additional grace period, through August 13, 2024, to regain compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. Although we do not intend to effect a reverse split of the Company's issued and outstanding voting common stock at the present time, seeking the discretion to implement actions, if necessary to maintain Jaguar's Nasdaq listing, is an important responsibility of the Board, and we are grateful to our shareholders for voting to approve the related proposal," said Lisa Conte, Jaguar's president, and CEO. Jaguar's paramount near-term clinical activity is the Company's Phase 3 pivotal OnTarget trial of crofelemer for the follow-on indication of the preventative treatment of cancer therapy-related diarrhea. Top line results from this pivotal study are forthcoming.

??? Na dann hau mal raus... Ich finde keine?!

Die Phase 3 Ergebnisse sind wohl da

“As we announced last week, the Company received formal notice that the Listing Qualifications Staff of The Nasdaq Stock Market LLC has granted Jaguar an additional grace period, through August 13, 2024, to regain compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. Although we do not intend to effect a reverse split of the Company’s issued and outstanding voting common stock at the present time, seeking the discretion to implement actions, if necessary to maintain Jaguar’s Nasdaq listing, is an important responsibility of the Board, and we are grateful to our shareholders for voting to approve the related proposal,” said Lisa Conte, Jaguar's president, and CEO.